Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Double-blind Trial of Suzetrigine in Total Hip Arthroplasty

NCT07226700 is registered in ClinicalTrials.gov with Hospital for Special Surgery, New York as lead sponsor.

NCT NCT07226700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07226700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Double-blind Trial of Suzetrigine in Total Hip Arthroplasty
Lead sponsor
Hospital for Special Surgery, New York
Phase
Phase 3
Overall status
Recruiting
Start date
November 3, 2025
Completion date
November 1, 2028
Enrollment
210 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

journavx, multimodal analgesia, nav 1.8, opioid cessation, opioid consumption, postoperative, pain, pain management, randomized controlled study, randomized controlled trial, randomized controlled trials, suzetrigine, total hip arthroplasty (tha), total hip arthroplasty \(tha\), total hip replacement, total hip replacement arthroplasty, total hip replacement surgery, total hip replacements